Augmenting antitumor T responses of viral cancer therapy by targeting myeloid-derived suppressor cells with an armed recombinant vaccinia virus

Dr Tan, Zhiwu   (Principal Investigator (PI))

Professor Chen Zhiwei   (Co-Investigator)

24

2018-09-01

1185048

Augmenting antitumor T responses of viral cancer therapy by targeting myeloid-derived suppressor cells with an armed recombinant vaccinia virus

CXCR2, immunosuppression, MDSCs, Oncolytic virus, peptibody, tumor immunotherapy

Others - Medicine, Dentistry and Health

05162326

Health and Medical Research Fund - Full Grant

2017

Completed

Oncolytic virus therapy is perhaps the next major breakthrough in cancer treatment following the success using immune checkpoint inhibitors. The advances achieved with recent clinical trials demonstrated that induction of specific antitumor immunity is crucial in prolonging survival of cancer patients. However, such responses especially T cell immunity are often suppressed under tumor environment. The overall objectives of the proposed study is to construct peptibody, peptide-Fc fusion protein, armed recombinant vaccinia virus targeting and depleting MDSCs to augment antitumor T cell responses for improvement of efficacy of oncolytic cancer therapy.